Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00002-2980-60 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
70710-1744-03 70710-1744 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
51407-0704-03 51407-0704 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jun 11, 2025 In Use
51407-0702-02 51407-0702 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jun 11, 2025 In Use
72205-0322-30 72205-0322 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 11, 2026 In Use
54868-5231-02 54868-5231 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jun 29, 2005 In Use
66993-0236-30 66993-0236 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
00002-6082-60 00002-6082 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral Apr 10, 2024 In Use
46708-0687-30 46708-0687 DASATINIB DASATINIB 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 11, 2025 In Use
51407-0702-06 51407-0702 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jun 11, 2025 In Use
00003-0855-22 00003-0855 Dasatinib Sprycel 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct 28, 2010 In Use
70771-1904-03 70771-1904 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
72237-0105-01 72237-0105 Selinexor XPOVIO 80.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jan 5, 2026 In Use
00781-2322-68 00781-2322 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Dec 27, 2016 In Use
68001-0669-15 68001-0669 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 3, 2026 In Use
00310-1350-30 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 13, 2015 In Use
00006-0461-12 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Mar 26, 2003 In Use
57894-0080-90 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
51655-0809-04 51655-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov 7, 2022 In Use
00173-0447-04 00173-0447 Ondansetron Hydrochloride Zofran 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 11, 1993 Sep 30, 2014 No Longer Used
70934-0206-95 70934-0206 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 4, 2019 In Use
61919-0465-06 61919-0465 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan 1, 2014 In Use
55111-0154-05 55111-0154 Ondansetron Hydrochloride ONDANSETRON 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 26, 2006 In Use
68001-0247-01 68001-0247 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Mar 13, 2014 Feb 27, 2018 In Use
71335-2974-08 71335-2974 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 30, 2025 In Use

Found 12611 results — Export these results